Sp402
PANEL DISCUSSION
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates. These state-of-the art lectures provide a bench to bedside insights into how basic and translational researchers can impact precision gastrointestinal oncology.
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates. These state-of-the art lectures provide a bench to bedside insights into how basic and translational researchers can impact precision gastrointestinal oncology.
Presenters
Tracks
Related Products
ANTIBODY-DRUG CONJUGATES IN GASTROINTESTINAL CANCERS
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates…
LYNCH SYNDROME VACCINE: BENCH TO BEDSIDE
This sessions describes advances and applications in neoantigen discovery to design cancer vaccines for cancer prevention and personalized oncology, as well novel antibody-drug conjugates…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
